Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Efzofitimod · ATYR-1923

Fusion protein · developed by aTyr Pharma

Phase 3 Most advanced trial

ATYR Developer

3 Registered trials

What is Efzofitimod?

Efzofitimod (ATYR1923) is an intravenously infused agent given every four weeks in studies of interstitial lung disease, severe COVID-19 pneumonia and pulmonary sarcoidosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ATYR-1923, KRP-R120
Drug type: Fusion protein
Therapy area: Infectious disease, Respiratory
Developer: aTyr Pharma, Inc. (ATYR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: V5TNN0W368

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05415137	Phase 3	Pulmonary Sarcoidosis	Completed	ATYR
NCT05892614	Phase 2	Interstitial Lung Disease	Recruiting	ATYR
NCT04412668	Phase 2	SARS-CoV-2 (COVID-19) Severe Pneumonia	Completed	ATYR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Interstitial Lung DiseasePulmonary SarcoidosisSARS-CoV-2 (COVID-19) Severe Pneumonia

More from aTyr Pharma

ATYR1940 Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ATYR page.

Follow ATYR, the company behind Efzofitimod

See ATYR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATYR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z